Table 1 Patient characteristics and ctDNA status at 4 weeks after surgery
From: Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Patient characteristics | Category | ctDNA negative (n = 852), n (%) | ctDNA positive (n = 187), n (%) | P valuea |
|---|---|---|---|---|
Age (years) | Median (range) | 69 (25–93) | 67 (39–88) | |
≤ 70 | 478 (56.1) | 115 (61.5) | 0.18 | |
>70 | 374 (43.9) | 72 (38.5) | ||
Sex | Male | 433 (50.8) | 117 (62.6) | 0.003 |
Female | 419 (49.2) | 70 (37.4) | ||
ECOG performance status | 0 | 744 (87.3) | 165 (88.2) | 0.33 |
1 | 108 (12.7) | 22 (11.8) | ||
Primary location | Right-sided colon | 349 (41.1) | 53 (28.6) | 0.001 |
Left-sided colon | 452 (53.2) | 113 (61.1) | ||
Rectum | 48 (5.7) | 19 (10.3) | ||
Pathological T stage | T1–T2 | 117 (15.9) | 7 (5.0) | <0.001 |
T3–T4 | 619 (84.1) | 133 (95.0) | ||
Pathological N stage | N0 | 402 (54.7) | 34 (24.3) | <0.001 |
N1–N2 | 333 (45.3) | 106 (75.7) | ||
Pathological stage | Stage I | 95 (11.1) | 2 (1.1) | <0.001 |
Stage II | 291 (34.1) | 24 (12.8) | ||
Stage III | 306 (36.0) | 91 (48.7) | ||
Stage IV or recurrence | 160 (18.8) | 70 (37.4) | ||
RAS and BRAF status | RAS and BRAF wild-type | 422 (49.5) | 94 (50.3) | 0.02 |
RAS mutant | 352 (41.3) | 87 (46.5) | ||
BRAF mutant | 78 (9.2) | 6 (3.2) | ||
MSI status | MSI-high | 95 (11.2) | 5 (2.7) | <0.001 |
MSS | 757 (88.8) | 182 (97.3) |
